LipoScience
LipoScience is a highly innovative, diagnostic company focused on changing the way heart disease, diabetes* and other metabolic diseases are assessed and managed.
We develop proprietary tests based on Nuclear Magnetic Resonance (NMR), an information-rich technology that produces a digital representation of the molecules present in a simple blood sample.
Over 6 million NMR LipoProfile® tests have been ordered by physicians. This test directly measures lipoprotein particles and provides physicians and their patients more information to manage their risk for heart disease and diabetes.
The company is preparing to decentralize its proprietary platform with a broad array of high value NMR based assays, in support of driving toward new clinical standards of care.
We have broad opportunities for growth in our diagnostic, research, and laboratory businesses. We are actively pursuing these opportunities with the support of our employees, our customers, and our industry partners.
* The LP-IR test is only available through the LipoScience laboratory.
News
January 5, 2012
LipoScience submits FDA 510(K) for Vantera® Clinical Analyzer. Click here to view the press release.October 6, 2011
Published opinion of National Lipid Association expert panel advises testing of LDL particle number to assess and manage cardiovascular risk. Click here to view the press releaseJune 9, 2011
LipoScience launches new website for the NMR LipoProfile test—The Particle Test. Click here to visit theparticletest.comJune 1, 2011
LipoScience surpasses six million NMR LipoProfile tests orderedApril 5, 2011
Data suggests LDL Particles may be more strongly associated with atherosclerosis than LDL cholesterolMarch 28, 2011
LipoScience appoints Robert J. Greczyn, Jr. and Dr. Woodrow A. Myers, Jr. to Board of DirectorsMarch 18, 2011
Clinical study demonstrates LDL particles are more strongly associated with cardiovascular events than LDL cholesterol
